Neutralization of extrapyramidal side-effects with Methixene.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D010276:Parasympatholytics / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D011618:Psychotic Disorders / Q000188:drug therapy; D012737:Sex Factors; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000009:adverse effects
D010276:Parasympatholytics; D010880:Piperidines; D010919:Placebos; D014149:Tranquilizing Agents; D014282:Trihexyphenidyl